Odile Jaume to Lead Telix’s European Operations
Melbourne (Australia) and Brussels (Belgium) – 1st of March, 2018. Telix Pharmaceuticals Limited (ASX:TLX) (“Telix”, the “Company”), an clinical-stage biopharmaceutical company focused on...
Telix has established several EU/UK entities as part of delivering the Company’s intellectual property management, clinical operations and manufacturing activities in Europe. Telix is currently executing a significant portfolio of clinical research activities in Europe to support key clinical trials for TLX-250 and TLX-101, as well as indication expansion for Telix’s pipeline. Telix Co-Founder and CEO Dr. Christian Behrenbruch stated, “It’s my great pleasure to welcome Odile to the team, and for her to take charge of our European operations. Europe has a highly sophisticated nuclear medicine ecosystem that Odile knows very well, and we are pleased to have the benefit of her managerial and business development acumen.”
To read the full media release click here
Webcast of CEO’s presentation to Jefferies 2019 London Healthcare Conference
Melbourne (Australia) – 25th November 2019. Telix Pharmaceuticals Limited has today announced that Group CEO, Dr Christian Behrenbruch, presented at...
Telix Pharmaceuticals Program Update Q3 2019
MELBOURNE (Australia) – Nov. 4, 2019 - Telix Pharmaceuticals Ltd Program Update Q3, 2019
Telix Pharmaceuticals and AusHealth to Partner on Novel Therapeutics for Lung, Ovarian Cancer
Melbourne and Adelaide (Australia) – 30 October 2019. Telix Pharmaceuticals Limited has today announced that Telix and AusHealth have entered...
Dr. Christian Behrenbruch, CEO of Telix Pharmaceuticals Limited, to speak at Jefferies 2019 London Healthcare Conference
LONDON (United Kingdom) – November 19, 2019 – Dr. Christian Behrenbruch, CEO of Telix Pharmaceuticals Limited, to speak at Jefferies...